Facioscapulohumeral muscular dystrophy
Drug research and approvals for facioscapulohumeral muscular dystrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 19 studies of facioscapulohumeral muscular dystrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 0 approved and 9 open orphan designations naming it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 19 recruiting on ClinicalTrials.gov ↗- A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in…NCT07798609 · Phase 1 / Phase 2 · Soufflé Therapeutics, Inc. · starts Sep 1, 2026
- Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDNCT07435129 · Phase 2 · Scholar Rock, Inc. · starts Jul 30, 2026
- Amino Acids and Exercise in FSHDNCT07543016 · Not applicable · University of Pavia · starts Apr 8, 2026
- Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)NCT07086521 · Phase 1 · Restem, LLC. · starts Dec 1, 2025
- Clenbuterol to Target DUX4 in FSHDNCT06721299 · Phase 1 · Jeffrey Statland · starts Jun 25, 2025
- A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDNCT07038200 · Phase 3 · Avidity Biosciences, Inc. · starts Jun 10, 2025
- Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)NCT06847282 · Not reported · University of Kansas Medical Center · starts May 22, 2025
- Personalized Training for People With Rare Neuromuscular DisordersNCT06708468 · Not applicable · Oslo University Hospital · starts Dec 13, 2024
- Ten Year Follow-up in FSHD: the FOCUS 3 StudyNCT06911190 · Not reported · Radboud University Medical Center · starts Sep 1, 2024
- BetterLife FSHD: A Patient-driven Health and Research PlatformNCT07409142 · Not reported · FSHD Society · starts Aug 2, 2024
Trials Authorized in Canada
Newest first; search them all in Canada trials| Aug 12, 2025 | A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of intravenous aoc 1020 for the treatment of…AOC 1020 | AVIDITY BIOSCIENCES | Ongoing |
| Aug 15, 2024 | A phase 2 open-label extension study to evaluate the long-term safety, tolerability, efficacy, and pharmacokinetics of aoc 1020 administered intravenously to…AOC 1020 | AVIDITY BIOSCIENCES | Ongoing |
| Apr 11, 2024 | A bicentric, randomized, double blind, placebo-controlled pilot study to evaluate the efficacy and safety of satralizumab in fshd1ENSPRYNG | OTTAWA HOSPITAL RESEARCH INSTITUTE | Ongoing |
| Feb 6, 2024 | A phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of aro-dux4 in adult patients and adolescent…SRP-1001 (ARO-DUX4, ADS-010) | Sarepta Therapeutics | Ongoing |
| Mar 17, 2023 | A randomized, double-blind, placebo-controlled, phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory…DELPACIBART BRAXLOSIRAN (AOC 1020) | AVIDITY BIOSCIENCES | Closed |
| Feb 18, 2019 | An open-label extension study to evaluate the long-term effects of ace-083 in patients with fshd previously enrolled in study a083-02 and in patients with cmt…ACE-083 | ACCELERON PHARMA INC | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Aug 13, 2026 | apitegromabtreatment of facioscapulohumeral muscular dystrophy | Scholar Rock, Inc. | Designated |
| Feb 2, 2026 | double homeobox 4 -anti-sense oligonucleotidetreatment of facioscapulohumeral muscular dystrophy | Solve FSHD | Designated |
| Nov 19, 2025 | small molecule inhibitor of the DUX4 transcription factortreatment of facioscapulohumeral muscular dystrophy | Altay Therapeutics | Designated |
| Oct 16, 2024 | AAV-based gene therapy expressing artificial microRNA…treatment of facioscapulohumeral muscular dystrophy | Armatus Bio | Designated |
| Nov 14, 2023 | Adeno-Associated Viral Vector Expressing Clustered…Treatement of facioscapulohumeral muscular dystrophy | EpiCrispr Biotechnologies, Inc. | Designated |
| Feb 13, 2023 | An antibody oligonucleotide conjugate, comprised of a human…Treatment of facioscapulohumeral muscular dystrophy (FSHD) | Avidity Biosciences, Inc. | Designated |
| Jan 6, 2022 | nandroloneTreatment of facioscapulohumeral muscular dystrophy | Sarcomed AB | Designated |
| Jan 27, 2020 | losmapimodTreatment of Facioscapulohumeral muscular dystrophy | Fulcrum Therapeutics, Inc. | Designated |
| May 23, 2018 | rebastinibTreatment of Facioscapulohumeral Muscular Dystrophy | Genea Biocells US Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA